Free Trial

Acurx Pharmaceuticals (ACXP) to Release Earnings on Tuesday

Acurx Pharmaceuticals logo with Medical background

Key Points

  • Acurx Pharmaceuticals is set to announce its Q2 2025 earnings on Tuesday, August 12th, with analysts expecting a loss of ($0.10) per share.
  • The company recently reported a quarterly loss of ($0.11) per share, exceeding expectations of ($0.14) by $0.03.
  • Acurx Pharmaceuticals has seen its stock price increase by 1,746.6%, with current trading at $5.67 after a significant rise from a low of $0.28.
  • Looking to Export and Analyze Acurx Pharmaceuticals Data? Unlock 5 Weeks of MarketBeat All Access for Just $5. Claim Your Limited-Time Discount.

Acurx Pharmaceuticals (NASDAQ:ACXP - Get Free Report) is projected to issue its Q2 2025 quarterly earnings data before the market opens on Tuesday, August 12th. Analysts expect Acurx Pharmaceuticals to post earnings of ($0.10) per share for the quarter.

Acurx Pharmaceuticals (NASDAQ:ACXP - Get Free Report) last released its earnings results on Monday, May 12th. The company reported ($2.20) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($2.80) by $0.60. On average, analysts expect Acurx Pharmaceuticals to post $-1 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Acurx Pharmaceuticals Price Performance

NASDAQ:ACXP opened at $5.05 on Thursday. Acurx Pharmaceuticals has a 1-year low of $4.91 and a 1-year high of $47.80. The firm has a market cap of $7.78 million, a PE ratio of -0.36 and a beta of -1.27. The firm has a 50 day simple moving average of $8.76 and a 200-day simple moving average of $9.86.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a "buy" rating and set a $160.00 price objective on shares of Acurx Pharmaceuticals in a research note on Thursday, May 15th.

Get Our Latest Research Report on Acurx Pharmaceuticals

About Acurx Pharmaceuticals

(Get Free Report)

Acurx Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections.

Read More

Earnings History for Acurx Pharmaceuticals (NASDAQ:ACXP)

Should You Invest $1,000 in Acurx Pharmaceuticals Right Now?

Before you consider Acurx Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Acurx Pharmaceuticals wasn't on the list.

While Acurx Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Overlooked AI Stocks That Chipmakers Can’t Live Without
Palantir & AMD Earnings: Massive Options Setups Ahead
3 Value Plays Set to Explode

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines